參考文獻 |
1. Sun, W., et al., microRNA: a master regulator of cellular processes for bioengineering systems. Annu Rev Biomed Eng, 2010. 12: p. 1-27.
2. Doench, J.G. and P.A. Sharp, Specificity of microRNA target selection in translational repression. Genes Dev, 2004. 18(5): p. 504-11.
3. Lewis, B.P., C.B. Burge, and D.P. Bartel, Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell, 2005. 120(1): p. 15-20.
4. He, L. and G.J. Hannon, MicroRNAs: small RNAs with a big role in gene regulation. Nature Reviews Genetics, 2004. 5(7): p. 522-531.
5. Zhang, L., et al., microRNAs exhibit high frequency genomic alterations in human cancer. Proceedings of the National Academy of Sciences, 2006. 103(24): p. 9136-9141.
6. Zhang, Y., P. Yang, and X.F. Wang, Microenvironmental regulation of cancer metastasis by miRNAs. Trends Cell Biol, 2014. 24(3): p. 153-60.
7. Kosaka, N., H. Iguchi, and T. Ochiya, Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci, 2010. 101(10): p. 2087-92.
8. Mirna Therapeutics, I. Pipeline. June 30, 2014]; Available from: http://www.mirnatherapeutics.com/___Pipeline/Pipeline.aspx.
9. Zhang, W. and H.T. Liu, MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res, 2002. 12(1): p. 9-18.
10. Schulze, W.X., L. Deng, and M. Mann, Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol Syst Biol, 2005. 1: p. 2005 0008.
11. Gray-Schopfer, V., C. Wellbrock, and R. Marais, Melanoma biology and new targeted therapy. Nature, 2007. 445(7130): p. 851-857.
12. Montagut, C. and J. Settleman, Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett, 2009. 283(2): p. 125-34.
13. (NCI), N.C.I. Melanoma Treatment (PDQ®). June 30, 2014]; Available from: http://www.cancer.gov/cancertopics/pdq/treatment/melanoma/Patient.
14. UK, C.R. Skin cancer incidence statistics. June 30, 2014]; Available from: http://www.cancerresearchuk.org/cancer-info/cancerstats/types/skin/incidence/uk-skin-cancer-incidence-statistics.
15. foundation, S.c. Guide to Staging-Melanoma. June 30, 2014]; Available from: http://www.skincancer.org/skin-cancer-information/melanoma/the-stages-of-melanoma/guide-to-staging-melanoma.
16. Parkin, D.M., et al., Global Cancer Statistics, 2002. CA: A Cancer Journal for Clinicians, 2005. 55(2): p. 74-108.
17. Siegel, R., D. Naishadham, and A. Jemal, Cancer statistics, 2013. CA Cancer J Clin, 2013. 63(1): p. 11-30.
18. Linos, E., et al., Increasing burden of melanoma in the United States. J Invest Dermatol, 2009. 129(7): p. 1666-74.
19. Davies, H., et al., Mutations of the BRAF gene in human cancer. Nature, 2002. 417(6892): p. 949-954.
20. Maldonado, J.L., et al., Determinants of BRAF Mutations in Primary Melanomas. Journal of the National Cancer Institute, 2003. 95(24): p. 1878-1890.
21. Lovly, C.M., et al., Routine Multiplex Mutational Profiling of Melanomas Enables Enrollment in Genotype-Driven Therapeutic Trials. PLoS ONE, 2012. 7(4): p. e35309.
22. Roberts, P.J. and C.J. Der, Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene, 2007. 26(22): p. 3291-3310.
23. Kwong, L.N. and M.A. Davies, Targeted therapy for melanoma: rational combinatorial approaches. Oncogene, 2014. 33(1): p. 1-9.
24. MedlinePlus. Vemurafenib. June 30, 2014]; Available from: http://www.nlm.nih.gov/medlineplus/druginfo/meds/a612009.html.
25. Lito, P., et al., Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas. Cancer Cell, 2012. 22(5): p. 668-682.
26. miRBase. Browse miRBase by species. July 3, 2014]; Available from: http://www.mirbase.org/cgi-bin/browse.pl.
27. Glud, M. and R. Gniadecki, MicroRNAs in the pathogenesis of malignant melanoma. J Eur Acad Dermatol Venereol, 2013. 27(2): p. 142-50.
28. Segura, M.F., et al., MicroRNA and cutaneous melanoma: from discovery to prognosis and therapy. Carcinogenesis, 2012. 33(10): p. 1823-32.
29. Kozubek, J., et al., In-depth characterization of microRNA transcriptome in melanoma. PLoS One, 2013. 8(9): p. e72699.
30. Hideshima, T. and K.C. Anderson, Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer, 2002. 2(12): p. 927-937.
31. Tesio, M. and A. Trumpp, Breaking the cell cycle of HSCs by p57 and friends. Cell Stem Cell, 2011. 9(3): p. 187-92.
32. Vaira, V., et al., microRNA profiles in coeliac patients distinguish different clinical phenotypes and are modulated by gliadin peptides in primary duodenal fibroblasts. Clin Sci (Lond), 2014. 126(6): p. 417-23.
33. Volinia, S., et al., A microRNA expression signature of human solid tumors defines cancer gene targets. Proceedings of the National Academy of Sciences of the United States of America, 2006. 103(7): p. 2257-2261.
34. Guan, H., et al., Down-regulation of miR-218-2 and its host gene SLIT3 cooperate to promote invasion and progression of thyroid cancer. J Clin Endocrinol Metab, 2013. 98(8): p. E1334-44.
35. Zhang, S., et al., MicroRNA-520e suppresses growth of hepatoma cells by targeting the NF-[kappa]B-inducing kinase (NIK). Oncogene, 2012. 31(31): p. 3607-3620.
36. Endo, H., et al., Potential of tumor-suppressive miR-596 targeting LGALS3BP as a therapeutic agent in oral cancer. Carcinogenesis, 2013. 34(3): p. 560-9.
37. Anwar, S.L. and U. Lehmann, DNA methylation, microRNAs, and their crosstalk as potential biomarkers in hepatocellular carcinoma. World J Gastroenterol, 2014. 20(24): p. 7894-7913.
38. Wang, F., et al., Multiple Regression Analysis of mRNA-miRNA Associations in Colorectal Cancer Pathway. Biomed Res Int, 2014. 2014: p. 676724. |